AlphaQuest LLC Sells 20,307 Shares of Amphastar Pharmaceuticals, Inc. $AMPH

AlphaQuest LLC cut its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 70.3% during the 3rd quarter, Holdings Channel.com reports. The firm owned 8,575 shares of the company’s stock after selling 20,307 shares during the quarter. AlphaQuest LLC’s holdings in Amphastar Pharmaceuticals were worth $229,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in AMPH. New York State Common Retirement Fund raised its position in shares of Amphastar Pharmaceuticals by 86.4% in the third quarter. New York State Common Retirement Fund now owns 90,169 shares of the company’s stock valued at $2,403,000 after purchasing an additional 41,800 shares during the period. SummerHaven Investment Management LLC purchased a new position in Amphastar Pharmaceuticals in the 3rd quarter valued at approximately $1,018,000. Y Intercept Hong Kong Ltd raised its holdings in Amphastar Pharmaceuticals by 41.5% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 25,090 shares of the company’s stock valued at $669,000 after acquiring an additional 7,363 shares during the period. Arkadios Wealth Advisors lifted its position in shares of Amphastar Pharmaceuticals by 2.4% during the third quarter. Arkadios Wealth Advisors now owns 36,008 shares of the company’s stock worth $960,000 after acquiring an additional 845 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 96.4% in the third quarter. Campbell & CO Investment Adviser LLC now owns 44,068 shares of the company’s stock worth $1,174,000 after acquiring an additional 21,635 shares during the period. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Stock Down 0.1%

Shares of AMPH opened at $28.57 on Wednesday. Amphastar Pharmaceuticals, Inc. has a 1 year low of $20.39 and a 1 year high of $32.69. The company has a debt-to-equity ratio of 0.78, a current ratio of 3.12 and a quick ratio of 2.21. The stock has a 50 day simple moving average of $26.91 and a two-hundred day simple moving average of $26.59. The firm has a market cap of $1.31 billion, a P/E ratio of 12.64, a P/E/G ratio of 5.07 and a beta of 0.88.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on AMPH shares. Needham & Company LLC dropped their price objective on Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Zacks Research downgraded shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, November 14th. Barclays assumed coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, December 9th. They set an “equal weight” rating and a $30.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $31.00.

Insider Activity at Amphastar Pharmaceuticals

In other news, Director Floyd F. Petersen sold 16,679 shares of the firm’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $26.49, for a total transaction of $441,826.71. Following the transaction, the director directly owned 75,531 shares of the company’s stock, valued at approximately $2,000,816.19. This trade represents a 18.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Rong Zhou sold 9,787 shares of Amphastar Pharmaceuticals stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $26.20, for a total value of $256,419.40. Following the completion of the transaction, the executive vice president owned 138,043 shares in the company, valued at approximately $3,616,726.60. This represents a 6.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 34,808 shares of company stock valued at $919,002. Insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.